Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease
Open Access
- 8 January 2026
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (1) , e71049
Abstract
INTRODUCTION: Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS: Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD). RESULTS: NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non‐carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross‐sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p‐tau217 and other phospho‐tau species. DISCUSSION: Together, our results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related clinical, cognitive, and biomarker outcomes. Highlights: Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non‐carrier family members, our results suggest that plasma N‐terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β‐amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related tau pathology and neurodegeneration across a wide spectrum of disease.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP23dk0207066)
- Japan Agency for Medical Research and Development (JP22dk0207049)
- National Institute on Aging (R01AG071865)
- Instituto de Salud Carlos III
- Korea Dementia Research Center
- Korea Health Industry Development Institute
- Alzheimer's Association (SG‐20‐690363‐DIAN)
This publication has 43 references indexed in Scilit:
- Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study GroupPLOS ONE, 2016
- C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell DeathJournal of Neuroscience, 2015
- Partial volume correction in quantitative amyloid imagingNeuroImage, 2015
- Symptom onset in autosomal dominant Alzheimer diseaseNeurology, 2014
- Quantitative Analysis of PiB-PET with FreeSurfer ROIsPLOS ONE, 2013
- Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s diseaseProceedings of the National Academy of Sciences, 2013
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- FreeSurferNeuroImage, 2012
- Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's diseaseAlzheimer's Research & Therapy, 2010
- Automatically Parcellating the Human Cerebral CortexCerebral Cortex, 2004